Brief: Baudax Bio Reports Q3 2022 Results
08/11/2022 22:37
Nov 8 (Reuters) - Baudax Bio Inc BXRX.O :
* BAUDAX BIO REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS
AND
BUSINESS HIGHLIGHTS
* BAUDAX BIO INC Q3 LOSS PER SHARE $2.47
* BAUDAX BIO INC QTRLY NET PRODUCT REVENUE RELATED TO SALES
OF
ANJESO IN U.S. $0.2 MILLION VERSUS $0.3 MILLION
Source text for Eikon: ID:nGNX235B51
Further company coverage: BXRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Baudax Bio
See all newsBrief: Baudax Bio On Feb 22, Filed Voluntary Petition Under Chapter 11 Of U.S. Bankruptcy Code
Brief: Baudax Bio Says Substantial Doubt Exists About Ability To Continue As A Going Concern For Next Twelve Months
Baudax Bio Inc expected to post a loss of 53 cents a share - Earnings Preview
Brief: Baudax Bio Says Phase 1/2a Clinical Study of TI-168 In Hemophilia A with FVIII Inhibitors Projected to Begin Q1 2024
Brief: Baudax Bio Inc - On October 5, 2023, Board Of Directors Of Company Appointed Natalie Mcandrew As Interim Chief Financial Officer